News

Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.

Data presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium show first-line Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with advanced gastroenteropancreatic neuroendocrine tumors.

All healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.

Application seeks approval for tumor-treating fields therapy combined with either an immune checkpoint inhibitor or docetaxel in patients with metastatic non-small cell lung cancer following progression on or after the use of platinum-based therapy.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

Pivmecillinam (Pivya) has a clinical cure rate of 95% in uncomplicated urinary tract infections and is recommended as a first-line option for treatment in many countries.

Data show daily oral dosing of NX-5948 in patients with relapsed or refractory B-cell malignancies experienced a clinical benefit across dose ranges from 50 mg to 200 mg.

Bloomlife’s MFM-Pro enables healthcare providers to measure maternal and fetal heart rate in the patient's home or clinic.

EdenHelp is expected to provide HCPs and patients with real-time access to Rx drug and medical device information.

Patients with chronic inflammatory demyelinating polyneuropathy administered HyQvia showed a statistically significant difference between relapse rates compared with placebo.

JAMA Health Forum details the DSCSA and stresses the value of protecting the pharmaceutical supply chain from adulterated products.

Researchers from the University of Cambridge collaborated with Pfizer to develop a platform combining automated experiments with artificial intelligence to predict chemical reactions.

Analysis examines how social and healthcare factors play a role.

Initiative seeks to find new therapies to improve the lives of patients with Rett syndrome.

The list price of Casgevy for transfusion-dependent beta thalassemia has yet to be released, however, the cost for the treatment in sickle cell disease is $2.2 million.

Zoryve (roflumilast) shows efficacy in seborrheic dermatitis and atopic dermatitis in clinical trials.

Cureus report discuss the value of AI, but the medical community must remain aware of privacy pitfalls.

Trial shows 52% of patients with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement administered Dupixent experienced a clinically meaningful reduction in itch on hands and feet vs. 14% with placebo.

Soaring healthcare costs show little sign of abating in 2024, and concerns about the affordability of medications and medical services continue to grow, despite investments in technology, clinical innovation, and efforts to manage utilization and waste.

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

IATA’s latest numbers suggest the strongest year-on-year growth in almost two years.

FDA approves Keytruda (pembrolizumab) combined with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer, which is the 39th overall approved indication for the drug in the United States.

The group—known as the Innovators' Network—is meant to serve as a link between entrepreneurs, providers, researchers, and payers while they strive to combat cardiovascular disease.

Morgan Company report makes the case for expanding coverage for GLP-1s beyond diabetes treatment and into the weight loss class, but are employers on board?

RemeGen Co. Ltd’s antibody-drug conjugate RC88 is being analyzed to treat platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

An overview of a structural approach that guides development of the analytics and related reporting that may assist brands in gaining or maintaining reimbursement positions and maximizing sales.